You are here: Industry Insights > tirzepatide

News List

BrainDos™ Formulated Dual GIP/GLP-1 Receptor Agonist Tirzepatide Outperforms Tirzepatide Solution (Mounjaro®) in Preclinical Study PharmaSources
October 15, 2024
MetP Pharma AG today announced tirzepatide in a BrainDos™ formulation reduced pro-inflammatory cytokine Il-6 by more than 80% and 2-fold stronger than with aqueous tirzepatide solution.
Lilly's SURPASS-2 Results Published in The New England Journal of Medicine Show Tirzepatide Achieved Superior A1C and Body Weight Reductions Compared to Injectable Semaglutide in Adults with Type 2 di drugs
July 01, 2021
Tirzepatide led to superior A1C and body weight reductions from baseline compared to injectable semaglutide 1 mg in 40-week results from Eli Lilly and Company's (NYSE: LLY) SURPASS-2 clinical trial.
Lilly’s tirzepatide beats Ozempic in head-to-head type 2 diabetes trial pharmatimes
June 29, 2021
Eli Lilly has announced that its investigational GIP and GLP-1 inhibitor tirzepatide showed superiority over Novo Nordisk’s Ozempic in a Phase III trial.
Lilly's SURPASS-1 results published in The Lancet show tirzepatide's superior A1C and body weight reductions versus placebo in adults with type 2 diabetes firstwordpharma
June 28, 2021
Tirzepatide led to superior A1C and body weight reductions from baseline across all three doses in adults with type 2 diabetes after 40 weeks of treatment in Eli Lilly and Company's (NYSE: LLY) SURPASS-1 monotherapy clinical trial evaluating the efficacy
Lilly’s tirzepatide achieves superior A1C reductions versus insulin glargine pharmatimes
May 25, 2021
Eli Lilly’s investigational candidate tirzepatide achieved superior A1C and body weight reductions compared with insulin glargine in adults with type 2 diabetes who have increased cardiovascular risk.
Lilly’s tirzepatide claims head-to-head trial win against injectable semaglutide pharmatimes
March 05, 2021
Eli Lilly’s investigational treatment tirzepatide has demonstrated superior A1C and body weight reduction compared to injectable semaglutide in adults with type 2 diabetes.
Lilly's Tirzepatide Reduced A1C, Body Weight for Type 2 Diabetes americanpharmaceuticalreview
December 10, 2020
Tirzepatide led to superior A1C and body weight reductions from baseline in adults with type 2 diabetes after 40 weeks of treatment in topline results from Eli Lilly and Company's SURPASS-1 monotherapy clinical trial evaluating the efficacy and safety ...